Characteristics of seroconverter groups
| Subject . | Group . | Age (y) . | Follow-up (mo) . | Baseline CD4+ (per mm3) . | ΔCD4+ (per mm3 per mo) . | Baseline CD4+ development (per lobe/ 104 input) . | ΔCD4+ development (per lobe/ 104 input per mo) . |
|---|---|---|---|---|---|---|---|
| 424 | Prog | 47 | 37.9 | 860 | 34 | 16.6 | 1.4 |
| 656 | Prog | 40 | 73 | 620 | 7 | 52.1 | 0.7 |
| 1029 | Prog | 51 | 100.3 | 590 | 5.4 | 38.3 | 0.4 |
| 1031 | Prog | 57 | 105.6 | 790 | 6.9 | 34.5 | 0.3 |
| 1091 | Prog | 46 | 64.2 | 770 | 11.1 | 149 | 2.3 |
| 1094 | Prog | 52 | 61.7 | 720 | 10.7 | 78.5 | 1.2 |
| 1112 | Prog | 48 | 68.3 | 570 | 8.1 | 80.1 | 1 |
| Mean | 48.7 | 73 | 754 | 9.4 | 62.4 | 1 | |
| 545 | LTNP | 58 | 101.7 | 880 | 4.8 | 25.4 | 0.2 |
| 658 | LTNP | 49 | 97.2 | 620 | 0 | 34.4 | 0.3 |
| 1024 | LTNP | 53 | 104 | 520 | 0.9 | 70 | 0.5 |
| 1140 | LTNP | 48 | 93.6 | 630 | 2.4 | 17.6 | 0.1 |
| 1160 | LTNP | 46 | 68.6 | 720 | 0 | 24.8 | 0.3 |
| 1171 | LTNP | 40 | 94.5 | 830 | 2.3 | 112.8 | +0.2 |
| 1194 | LTNP | 51 | 96 | 790 | 3.3 | 24.1 | +0.2 |
| Mean | 49.3 | 93.7 | 711 | 2.0 | 44.2 | 0.1 |
| Subject . | Group . | Age (y) . | Follow-up (mo) . | Baseline CD4+ (per mm3) . | ΔCD4+ (per mm3 per mo) . | Baseline CD4+ development (per lobe/ 104 input) . | ΔCD4+ development (per lobe/ 104 input per mo) . |
|---|---|---|---|---|---|---|---|
| 424 | Prog | 47 | 37.9 | 860 | 34 | 16.6 | 1.4 |
| 656 | Prog | 40 | 73 | 620 | 7 | 52.1 | 0.7 |
| 1029 | Prog | 51 | 100.3 | 590 | 5.4 | 38.3 | 0.4 |
| 1031 | Prog | 57 | 105.6 | 790 | 6.9 | 34.5 | 0.3 |
| 1091 | Prog | 46 | 64.2 | 770 | 11.1 | 149 | 2.3 |
| 1094 | Prog | 52 | 61.7 | 720 | 10.7 | 78.5 | 1.2 |
| 1112 | Prog | 48 | 68.3 | 570 | 8.1 | 80.1 | 1 |
| Mean | 48.7 | 73 | 754 | 9.4 | 62.4 | 1 | |
| 545 | LTNP | 58 | 101.7 | 880 | 4.8 | 25.4 | 0.2 |
| 658 | LTNP | 49 | 97.2 | 620 | 0 | 34.4 | 0.3 |
| 1024 | LTNP | 53 | 104 | 520 | 0.9 | 70 | 0.5 |
| 1140 | LTNP | 48 | 93.6 | 630 | 2.4 | 17.6 | 0.1 |
| 1160 | LTNP | 46 | 68.6 | 720 | 0 | 24.8 | 0.3 |
| 1171 | LTNP | 40 | 94.5 | 830 | 2.3 | 112.8 | +0.2 |
| 1194 | LTNP | 51 | 96 | 790 | 3.3 | 24.1 | +0.2 |
| Mean | 49.3 | 93.7 | 711 | 2.0 | 44.2 | 0.1 |
Prog, progressor; LTNP, long-term nonprogressor.
Follow-up was the time from the known seroconversion date to AIDS diagnosis in the progressors and to approximately 8 years after seroconversion in the LTNPs. Baseline CD4+ counts and CD4+ T-cell development were from a sample at least 1 year before seroconversion. CD4+ T-cell development is expressed as the number of CD4+ cells that developed in FTOC per 104 cells in the original inoculum. ΔCD4+ is the loss of CD4+ T cells per month during follow-up. ΔCD4+ development was the change in development in FTOC during the entire course of follow-up.